CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03376659
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:59.601700+00:00
Published At: 2023-01-10T00:00:00+00:00
Record Updated At: 2024-02-05
Results Posted At: 2023-01-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Metastatic Colorectal Cancer", "Colorectal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Metastatic Pancreatic Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-02-05"
protocolSection.identificationModule.nctId: "NCT03376659"
protocolSection.identificationModule.officialTitle: "A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-01-10"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.